The UAB Cancer Outreach Program of the MSM/TU/UAB Partnership seeks to increase the accrual of African Americans into cancer clinical trials. Its goals are to 1) train Community Health Advisors (CHAs) as patient navigators to assist African American cancer patients overcome barriers to participation in cancer clinical trials;2) increase the recruitment and retention of African American cancer patients in therapeutic cancer clinical trials at UAB and Cooper Green Mercy Hospital (CGMH);3) develop and implement a culturally appropriate awareness of clinical trials and an educational program targeting African Amencan communities in the area surrounding Birmingham (in Jefferson County, Alabama);4) Develop a clinical trial infrastructure to provide CGMH patients with access to cancer clinical trials. Based on the demonstrated feasibility of IMPaCT, the effectiveness ofthe model in a hypothesis-driven research design will be evaluated. Building on the success of our Patient Navigator program for patients with abnormal breast mammograms and/or breast cancer, and on our experience with recruitment to cancer clinical trials, our innovative community-based program provides opportunities for African Americans diagnosed with cancer to participate in state-of-the-art cancer therapies. Increased participation of African Americans in clinical trials will contributes to the elimination of cancer health disparities.

Public Health Relevance

The UAB Cancer Outreach Program is directly relevant to the Partnership's goal of contributing to the elimination ofthe gap in cancer morbidity and mortality. The Patient Navigation Program creates an infrastructure for cancer clinical trials that enhances the participation of African Americans in therapeutic studies, thereby improving the translation of scientific discoveries to the African American community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA118948-09
Application #
8936035
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (O1))
Program Officer
Ogunbiyi, Peter
Project Start
2005-09-30
Project End
2016-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
$98,814
Indirect Cost
$30,841
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Luo, Yanzhuo; Li, Bingjin; Zhang, Guangxin et al. (2018) Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion. J Cancer 9:1096-1105
Wang, Chiung-Min; Yang, William H; Liu, Runhua et al. (2018) FOXP3 Activates SUMO-Conjugating UBC9 Gene in MCF7 Breast Cancer Cells. Int J Mol Sci 19:
Moore, Justin Xavier; Royston, Kendra J; Langston, Marvin E et al. (2018) Mapping hot spots of breast cancer mortality in the United States: place matters for Blacks and Hispanics. Cancer Causes Control :
Akinyemiju, Tomi; Moore, Justin Xavier; Pisu, Maria et al. (2018) A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality. Obesity (Silver Spring) 26:193-201
Akinyemiju, Tomi; Moore, Justin Xavier; Judd, Suzanne E et al. (2018) Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget 9:16099-16109
Piyathilake, Chandrika J; Badiga, Suguna; Borak, Samuel G et al. (2017) A higher degree of expression of DNA methyl transferase 1 in cervical cancer is associated with poor survival outcome. Int J Womens Health 9:413-420
Williams, Samuel K; Braxton, Joanne M; Gosdin, Melissa et al. (2017) Evidence-Based Care for the Elderly: Uses of ""the Grandmother Principle"". J Health Care Poor Underserved 28:7
Gao, Song; Wang, Yicun; Wang, Meng et al. (2017) MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget 8:41451-41464
Jia, Xu; Shanmugam, Chandrakumar; Paluri, Ravi K et al. (2017) Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget 8:20198-20212
Zhang, Yifan; Li, Bingjin; Zhang, Xingyi et al. (2017) CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog 56:641-650

Showing the most recent 10 out of 193 publications